title: Raiding the pharmacy: genomic screening identifies known chemotherapies as negative regulators of MCL1.
abstract: Despite multiple studies demonstrating the importance of the anti-apoptotic protein Mcl-1 in tumor cell survival and treatment resistance, a clinically important inhibitor has yet to be developed. A recent study by Guo Wei and colleagues published in Cancer Cell has utilized a novel high-throughput approach to identify compounds that act as transcriptional repressors of MCL1 expression. Their findings identified a number of candidate drugs to be tested for clinical relevance in human cancers dependent on MCL1 expression.
authors: Department of Immunology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave/NE60, NE6-251, Cleveland, OH 44195-0002, USA. gastmab@ccf.org.
authors: Lukas W
authors: LW
authors: Pfannenstiel
authors: Abeba
authors: A
authors: Demelash
authors: Brian R
authors: BR
authors: Gastman